Zimbabwe Business News API

{
    "totalArticles": 862,
    "articles": [
        {
            "id": "0dc226b92c3de3eaa3e899b4a6b87a71",
            "title": "Qantas Economy Plus coming to 737s, A220s and A321XLRs",
            "description": "Qantas in February 2026 will introduce a new 'Qantas Economy Plus’ extra-legroom product on its 737s, A220s and A321XLRs.",
            "content": "When Qantas’ first two new 200-seat Airbus A321XLRs entered revenue service in September, some folks’ initial impressions were less than favorable due to the miserly passenger-to-toilet ratio in economy class, with one lavatory allocated for every 90... [5215 chars]",
            "url": "https://runwaygirlnetwork.com/2025/11/qantas-economy-plus-coming-to-737s-a220s-and-a321xlrs/",
            "image": "https://runwaygirlnetwork.com/wp-content/uploads/2025/11/Qantas-Plus-Imagery-Headrest-Seats.jpg",
            "publishedAt": "2025-11-08T21:54:48Z",
            "lang": "en",
            "source": {
                "id": "32d11a06da4ec2dd855deda0a2b5ad59",
                "name": "Runway Girl",
                "url": "https://runwaygirlnetwork.com"
            }
        },
        {
            "id": "629bbd21b195b6fdd4dad8122bc5d5fd",
            "title": "Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs",
            "description": "Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.",
            "content": "Pending the results of the ongoing phase 3 SORENTO trial (NCT05050942), increasing the dose or shortening the treatment interval of somatostatin analogs may be a viable route to take for patients with gastroenteropancreatic neuroendocrine tumors (GEP... [4218 chars]",
            "url": "https://www.onclive.com/view/chan-breaks-down-the-need-for-dose-escalation-with-somatostatin-analogs-in-gep-nets",
            "image": "https://cdn.sanity.io/images/0vv8moc6/onclive/e82fb5639847a35ed890075c76b6fb6d5852cef3-1280x720.png",
            "publishedAt": "2025-11-08T20:55:54Z",
            "lang": "en",
            "source": {
                "id": "0da2d0b1fc86b8b05e122c750c98bd32",
                "name": "OncLive",
                "url": "https://www.onclive.com"
            }
        },
        {
            "id": "8148edd54814d14f6d79c47425df0771",
            "title": "Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript",
            "description": "Hikma Pharmaceuticals PLC (OTCPK:HKMPY) Shareholder/Analyst Call November 6, 2025 4:30 AM ESTCompany ParticipantsRiad Mishlawi - Interim Head of Injectables...",
            "content": "Unknown Executive\nThank you. Before we start, we'd like to remind you that any forward-looking statements or projections made by Hikma during this call are made in good faith based on information currently available and subject to risks and uncertain... [838 chars]",
            "url": "https://seekingalpha.com/article/4840842-hikma-pharmaceuticals-plc-hkmpy-shareholder-analyst-call-transcript",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "publishedAt": "2025-11-08T19:26:09Z",
            "lang": "en",
            "source": {
                "id": "3c5f57e561d9315a8a9a86be8720511e",
                "name": "Seeking Alpha",
                "url": "https://seekingalpha.com"
            }
        }
    ]
}